RxDoctor Payments Data

Madison Bonvillion

Family · Beaumont, TXNPI 1053805986

Payments from drug & device makers

$453in general payments, 2019–2025

Across 22 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$124
  • Smith+Nephew$100
  • Urgo Medical North America, LLC$52
  • Organogenesis Inc.$51
  • Solventum Corporation$46
  • ETS Wound Care LLC$42
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$453 in reported general payments places this provider in the 50th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$38,133
Medicare patients
87
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nitro-BidNitroglycerin27$928
Doxycycline Monohydrate21$294

Paid to pharmacies, not to this prescriber.

Other family in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →